Who wins? Tirzepatide vs Semaglutide

Rarely in medicine are their head to head trials of pharmaceuticals. In the Surmount 5 Trial, researchers directly compare Semaglutide vs Tirzepatide in a phase 3b trial. The comparison was specifically for obesity and excluded patients with diabetes. For 18 months, 751 adults were trialed on either Semaglutide or Tirzepatide.

The results had significant weight loss for all participants. Tirzepatide had the most average weight loss. In fact, at the two max doses (10mg &15 mg), participants lost on average 20% of their body weight. This is about 22 kg or 50 pounds.

Semaglutide at the two max doses (1.7mg & 2.4 mg), had an average body weight loss of 13.7%. This equates to 15kg or 33 pounds.

In summary Tirzepatide had 47% or almost double the weight loss.